RE: WebcastManagement has always expressed to me that the hope for reolysin was first line treatment,such as would most likely be the case with glio.The worst case scenario is that the reo-virus could be used as a co-therapy.
They have not suggested what co-therapy would be used but there are a number of possiblilties,such as radiation or chemo.We must remember that onc would like to be a leading company in the treatment of cancer and a way to do this would be to also look at other viable companies that are in early stage phases.
The reo-virus would be obviously used for the ras-activated cancers and most likely used systemically to treat any metastisis.As the cancer spreads and mutates there are more chances for ras-activation.
Most people will die from complications as a result of the spread of the cancer so if this is a way of controlling the spread or metastisis throughout the body they hopefully this is where the other forms of treatments that are know today will take care of the original cancer or tumour if it is not ras-activated.
In the least it would appear that we are looking at life-extension which was expressed more than once at the Seattle conference.That is what the fda wants to hear and see.
Inthno